Citius Transnet InvIT IPO GMP today
The InvIT currently has a grey market premium (GMP) of zero, suggesting no immediate listing gains. This indicates the issue is priced in line with perceived fair value, with limited speculative demand in the unofficial market.
Given the nature of InvITs, which are typically yield-focused instruments rather than listing gain plays, muted GMP trends are not unusual.
Citius Transnet InvIT IPO details
The issue is a fresh issue of Rs 1,105 crore, comprising 11.05 crore units, with a price band of Rs 99–100 per unit. The offer will close on April 21, with allotment expected on April 24 and listing scheduled for April 29 on both BSE and NSE.
The allocation structure reserves up to 75% for institutional investors, while at least 25% is earmarked for non-institutional investors, in line with InvIT norms.
Subscription trend on Day 1
Early subscription data shows a lukewarm response, with the issue subscribed 0.5 times as of Day 1 afternoon, largely driven by non-institutional investors. The NII portion was subscribed to 1.11 times, while institutional participation remained subdued at the time of reporting.
Company overview and portfolio
Citius Transnet InvIT focuses on road infrastructure assets and manages a diversified portfolio spanning 3,406.71 lane-kilometres across nine states. The portfolio includes a mix of toll-based and annuity projects, providing a blend of traffic-linked and stable revenue streams.
The trust is backed by Epic TransNet Infrastructure and managed by EAAA India Alternatives, a notable infrastructure-focused investment platform with strong institutional backing.
Financials
The InvIT has reported net losses in recent years, including a loss of Rs 219 crore for the nine months ended December 2025, primarily due to high amortisation and financing costs, which are typical in infrastructure vehicles. Revenue during the same period stood at Rs 1,570 crore.
Investors generally evaluate InvITs based on cash flow visibility and distribution yield, rather than profitability metrics, making the underlying asset performance critical.
Listing outlook
With a zero GMP, moderate early subscription, and yield-focused structure, the listing is expected to remain around the issue price, with limited scope for short-term gains.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)